Zielinski, Mara http://orcid.org/0000-0001-7443-917X
Peralta Reyes, Fernanda S. http://orcid.org/0000-0001-8379-4827
Gremer, Lothar http://orcid.org/0000-0001-7065-5027
Schemmert, Sarah
Frieg, Benedikt http://orcid.org/0000-0002-7877-0262
Schäfer, Luisa U.
Willuweit, Antje http://orcid.org/0000-0002-6725-0755
Donner, Lili
Elvers, Margitta
Nilsson, Lars N. G. http://orcid.org/0000-0002-8362-1042
Syvänen, Stina http://orcid.org/0000-0002-8196-4041
Sehlin, Dag http://orcid.org/0000-0002-9430-3859
Ingelsson, Martin
Willbold, Dieter http://orcid.org/0000-0002-0065-7366
Schröder, Gunnar F. http://orcid.org/0000-0003-1803-5431
Funding for this research was provided by:
Helmholtz Association
Bundesministerium für Bildung und Forschung (16LW028)
Vetenskapsrådet (2021-03524, 2021-01083, 2021-03524, 2021-02793)
"Portfolio Drug Research" of the "Impuls und Vernetzungsfonds der Helmholtzgemeinschaft".
Article History
Received: 18 June 2023
Accepted: 6 October 2023
First Online: 16 November 2023
Competing interests
: L.N.G.N. is on the scientific advisory board and receives a research grant from BioArctic. M.I. is a paid consultant to BioArctic. D.W. is a founder and shareholder of the company Priavoid and a member of its supervisory board. D.W. is co-inventor of patents related to the compound RD2. D.W. is a founder and shareholder of attyloid. D.W. is a member of attyloid’s supervisory board. These had no influence on the interpretation of the data. Benedikt Frieg is now an AstraZeneca employee. All other authors declare no competing interests.